Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$201.3 million for Q3 2025.

• In Q3 2025, Cash from Investing Activities rose 22.4% year-over-year to -$201.3 million; the TTM figure through Sep 2025 stood at -$183.1 million (up 32.65% YoY), while the FY2024 annual figure was -$286.8 million, down 1516.15% from the prior year.
• Cash from Investing Activities for Q3 2025 stood at -$201.3 million, down from $26.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $29.9 million in Q2 2021, with the low at -$259.4 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is -$5.5 million (2024), against an average of -$23.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 17048.84% in 2023, then slumped 2154.36% in 2024.
• Dianthus Therapeutics' Cash from Investing Activities stood at -$10.3 million in 2021, then decreased by 22.69% to -$12.7 million in 2022, then surged by 34.96% to -$8.2 million in 2023, then plunged by 180.56% to -$23.1 million in 2024, then tumbled by 770.94% to -$201.3 million in 2025.
• Business Quant data shows DNTH's Cash from Investing Activities at -$201.3 million in Q3 2025, $26.4 million in Q2 2025, and $14.8 million in Q1 2025.